#begin document (bn/voa/00/voa_0061); part 000
bn/voa/00/voa_0061   0    0          And     CC     (TOP(S*        -    -   -   -        *      *    (ARGM-DIS*)    -
bn/voa/00/voa_0061   0    1           at     IN        (PP*        -    -   -   -        *      *    (ARGM-TMP*     -
bn/voa/00/voa_0061   0    2          one     CD     (NP(NP*        -    -   -   -   (TIME*      *             *     -
bn/voa/00/voa_0061   0    3        forty     CD           *        -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0    4           -    HYPH           *        -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0    5         five     CD           *)       -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0    6    Universal     JJ        (NP*        -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0    7         time     NN         *)))     time   -   5   -        *)     *             *)    -
bn/voa/00/voa_0061   0    8          you    PRP        (NP*)       -    -   -   -        *      *        (ARG0*)    -
bn/voa/00/voa_0061   0    9          are    VBP        (VP*        be  03   -   -        *    (V*)            *     -
bn/voa/00/voa_0061   0   10    listening    VBG        (VP*    listen  01   1   -        *      *           (V*)    -
bn/voa/00/voa_0061   0   11           to     IN        (PP*        -    -   -   -        *      *        (ARG1*     -
bn/voa/00/voa_0061   0   12          the     DT     (NP(NP*        -    -   -   -    (ORG*      *             *   (16
bn/voa/00/voa_0061   0   13        Voice    NNP           *)       -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0   14           of     IN        (PP*        -    -   -   -        *      *             *     -
bn/voa/00/voa_0061   0   15      America    NNP   (NP*))))))       -    -   -   -        *)     *             *)   16)
bn/voa/00/voa_0061   0   16            .      .          *))       -    -   -   -        *      *             *     -

bn/voa/00/voa_0061   0    0           Monkey    NN  (TOP(S(NP(NP*            -    -   -   -   *    (ARG1*)     *       (ARG0*        *   (19
bn/voa/00/voa_0061   0    1      experiments   NNS              *)   experiment  01   1   -   *       (V*)     *            *        *     -
bn/voa/00/voa_0061   0    2               by    IN           (PP*            -    -   -   -   *    (ARG0*      *            *        *     -
bn/voa/00/voa_0061   0    3               an    DT           (NP*            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0    4    international    JJ              *            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0    5         research    NN              *            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0    6             team    NN            *)))           -    -   -   -   *         *)     *            *)       *    19)
bn/voa/00/voa_0061   0    7             have   VBP           (VP*          have  01   -   -   *         *    (V*)           *        *     -
bn/voa/00/voa_0061   0    8         reversed   VBN           (VP*       reverse  01   1   -   *         *      *          (V*)       *     -
bn/voa/00/voa_0061   0    9              the    DT        (NP(NP*            -    -   -   -   *         *      *       (ARG1*        *     -
bn/voa/00/voa_0061   0   10            brain    NN              *            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   11     degeneration    NN              *)           -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   12          typical    JJ         (ADJP*            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   13               of    IN           (PP*            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   14        Parkinson   NNP        (NP(NP*            -    -   -   -   *         *      *            *        *   (14
bn/voa/00/voa_0061   0   15               's   POS              *)           -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   16          Disease   NNP           *))))           -    -   -   -   *         *      *            *)       *    14)
bn/voa/00/voa_0061   0   17               by    IN           (PP*            -    -   -   -   *         *      *   (ARGM-MNR*        *     -
bn/voa/00/voa_0061   0   18          placing   VBG         (S(VP*         place  01   1   -   *         *      *            *      (V*)    -
bn/voa/00/voa_0061   0   19           repair    NN           (NP*        repair   -   1   -   *         *      *            *   (ARG1*     -
bn/voa/00/voa_0061   0   20         proteins   NNS              *)           -    -   -   -   *         *      *            *        *)    -
bn/voa/00/voa_0061   0   21           inside    IN           (PP*            -    -   -   -   *         *      *            *   (ARG2*     -
bn/voa/00/voa_0061   0   22                a    DT           (NP*            -    -   -   -   *         *      *            *        *   (17
bn/voa/00/voa_0061   0   23         disabled    JJ              *            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   24             AIDS   NNP              *            -    -   -   -   *         *      *            *        *     -
bn/voa/00/voa_0061   0   25            virus    NN        *)))))))           -    -   -   -   *         *      *            *)       *)   17)
bn/voa/00/voa_0061   0   26                .     .             *))           -    -   -   -   *         *      *            *        *     -

bn/voa/00/voa_0061   0    0               As    IN  (TOP(S(SBAR*               -    -   -   -          *         *      *      *      *   (ARGM-ADV*        *        *      -
bn/voa/00/voa_0061   0    1               we   PRP        (S(NP*)              -    -   -   -          *    (ARG0*)     *      *      *            *        *        *    (16)
bn/voa/00/voa_0061   0    2             hear   VBP          (VP*             hear  01   1   -          *       (V*)     *      *      *            *        *        *      -
bn/voa/00/voa_0061   0    3             from    IN          (PP*               -    -   -   -          *    (ARG2*      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0    4            David   NNP          (NP*               -    -   -   -   (PERSON*         *      *      *      *            *        *        *    (21
bn/voa/00/voa_0061   0    5          McAlary   NNP         *)))))              -    -   -   -          *)        *)     *      *      *            *)       *        *     21)
bn/voa/00/voa_0061   0    6                ,     ,             *               -    -   -   -          *         *      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0    7              the    DT          (NP*               -    -   -   -          *         *      *      *      *       (ARG1*        *        *    (19
bn/voa/00/voa_0061   0    8             work    NN             *)            work  01   1   -          *         *    (V*)     *      *            *)       *        *     19)
bn/voa/00/voa_0061   0    9               is   VBZ          (VP*               be  03   -   -          *         *      *    (V*)     *            *        *        *      -
bn/voa/00/voa_0061   0   10            being   VBG          (VP*               be  03   -   -          *         *      *      *    (V*)           *        *        *      -
bn/voa/00/voa_0061   0   11           hailed   VBN          (VP*             hail  02   1   -          *         *      *      *      *          (V*)       *        *      -
bn/voa/00/voa_0061   0   12               as    IN          (PP*               -    -   -   -          *         *      *      *      *       (ARG2*        *        *      -
bn/voa/00/voa_0061   0   13                a    DT       (NP(NP*               -    -   -   -          *         *      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0   14     breakthrough    NN             *)    breakthrough  01   1   -          *         *      *      *      *            *      (V*)       *      -
bn/voa/00/voa_0061   0   15               in    IN          (PP*               -    -   -   -          *         *      *      *      *            *   (ARG1*        *      -
bn/voa/00/voa_0061   0   16               an    DT          (NP*               -    -   -   -          *         *      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0   17           effort    NN             *           effort   -   1   -          *         *      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0   18               to    TO        (S(VP*               -    -   -   -          *         *      *      *      *            *        *        *      -
bn/voa/00/voa_0061   0   19              end    VB          (VP*              end  01   2   -          *         *      *      *      *            *        *      (V*)     -
bn/voa/00/voa_0061   0   20        Parkinson   NNP   (NP(NML(NP*               -    -   -   -          *         *      *      *      *            *        *   (ARG1*    (14
bn/voa/00/voa_0061   0   21               's   POS            *))              -    -   -   -          *         *      *      *      *            *        *        *     14)
bn/voa/00/voa_0061   0   22    deterioration    NN   *)))))))))))   deterioration   -   2   -          *         *      *      *      *            *)       *)       *)     -
bn/voa/00/voa_0061   0   23                .     .            *))              -    -   -   -          *         *      *      *      *            *        *        *      -

bn/voa/00/voa_0061   0   0     Patients   NNS   (TOP(S(NP(NP*)     -    -   -   -   *   (ARG1*      *   (3
bn/voa/00/voa_0061   0   1         with    IN            (PP*      -    -   -   -   *        *      *    -
bn/voa/00/voa_0061   0   2     advanced    JJ            (NP*      -    -   -   -   *        *      *    -
bn/voa/00/voa_0061   0   3    Parkinson   NNP            (NP*      -    -   -   -   *        *      *    -
bn/voa/00/voa_0061   0   4           's   POS            *))))     -    -   -   -   *        *)     *    3)
bn/voa/00/voa_0061   0   5          are   VBP            (VP*      be  01   1   -   *      (V*)     *    -
bn/voa/00/voa_0061   0   6         easy    JJ          (ADJP*      -    -   -   -   *   (ARG2*      *    -
bn/voa/00/voa_0061   0   7           to    TO     (SBAR(S(VP*      -    -   -   -   *        *      *    -
bn/voa/00/voa_0061   0   8         spot    VB       (VP*))))))   spot  01   1   -   *        *)   (V*)   -
bn/voa/00/voa_0061   0   9            .     .              *))     -    -   -   -   *        *      *    -

bn/voa/00/voa_0061   0    0    Degeneration    NN   (TOP(S(NP(NP*)        -    -   -   -   *   (ARG0*         *         *         *     -
bn/voa/00/voa_0061   0    1              of    IN            (PP*         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0    2           brain    NN         (NP(NP*         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0    3           cells   NNS               *)      cell   -   1   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0    4              or    CC               *         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0    5         neurons   NNS         (NP*))))        -    -   -   -   *        *)        *         *         *     -
bn/voa/00/voa_0061   0    6          causes   VBZ            (VP*      cause  01   1   -   *      (V*)        *         *         *     -
bn/voa/00/voa_0061   0    7            them   PRP          (S(NP*)        -    -   -   -   *   (ARG1*    (ARG1*)   (ARG0*)   (ARG0*)   (3)
bn/voa/00/voa_0061   0    8              to    TO            (VP*         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0    9           shake    VB            (VP*      shake  01   1   -   *        *       (V*)        *         *     -
bn/voa/00/voa_0061   0   10               ,     ,               *         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0   11         shuffle    VB               *    shuffle  02   1   -   *        *         *       (V*)        *     -
bn/voa/00/voa_0061   0   12             and    CC               *         -    -   -   -   *        *         *         *         *     -
bn/voa/00/voa_0061   0   13           stoop    VB            *))))     stoop  01   3   -   *        *)        *         *       (V*)    -
bn/voa/00/voa_0061   0   14               .     .              *))        -    -   -   -   *        *         *         *         *     -

bn/voa/00/voa_0061   0    0         The    DT       (TOP(S(NP*         -    -   -   -   *   (ARG0*           *            *    (7
bn/voa/00/voa_0061   0    1     neurons   NNS                *)        -    -   -   -   *        *)          *            *     7)
bn/voa/00/voa_0061   0    2     produce   VBP             (VP*    produce  01   1   -   *      (V*)          *            *     -
bn/voa/00/voa_0061   0    3        less   JJR     (NP(NP(ADJP*         -    -   -   -   *   (ARG1*           *            *     -
bn/voa/00/voa_0061   0    4         and    CC                *         -    -   -   -   *        *           *            *     -
bn/voa/00/voa_0061   0    5        less   JJR               *))        -    -   -   -   *        *           *            *     -
bn/voa/00/voa_0061   0    6          of    IN             (PP*         -    -   -   -   *        *           *            *     -
bn/voa/00/voa_0061   0    7         the    DT       (NP(NP(NP*         -    -   -   -   *        *      (ARG0*            *     -
bn/voa/00/voa_0061   0    8    chemical    NN                *)        -    -   -   -   *        *           *            *     -
bn/voa/00/voa_0061   0    9    dopamine    NN            (NP*))        -    -   -   -   *        *           *)           *     -
bn/voa/00/voa_0061   0   10        that   WDT      (SBAR(WHNP*)        -    -   -   -   *        *    (R-ARG0*)           *     -
bn/voa/00/voa_0061   0   11       helps   VBZ           (S(VP*       help  01   1   -   *        *         (V*)           *     -
bn/voa/00/voa_0061   0   12       relay    VB           (S(VP*      relay  01   1   -   *        *      (ARG1*          (V*)    -
bn/voa/00/voa_0061   0   13     signals   NNS             (NP*)    signal   -   3   -   *        *           *       (ARG1*)    -
bn/voa/00/voa_0061   0   14     between    IN             (PP*         -    -   -   -   *        *           *   (ARGM-LOC*     -
bn/voa/00/voa_0061   0   15        them   PRP   (NP*)))))))))))        -    -   -   -   *        *)          *)           *)   (7)
bn/voa/00/voa_0061   0   16           .     .               *))        -    -   -   -   *        *           *            *     -

bn/voa/00/voa_0061   0    0         Dopamine    NN  (TOP(S(S(NP(NP*             -    -   -   -   *    (ARG1*)  (ARG1*            *        *    (11
bn/voa/00/voa_0061   0    1      replacement    NN                *)   replacement  01   1   -   *       (V*)       *            *        *      -
bn/voa/00/voa_0061   0    2             with    IN             (PP*             -    -   -   -   *    (ARG2*        *            *        *      -
bn/voa/00/voa_0061   0    3            drugs   NNS           (NP*)))            -    -   -   -   *         *)       *)           *        *     11)
bn/voa/00/voa_0061   0    4               is   VBZ             (VP*             be  01   1   -   *         *      (V*)           *        *      -
bn/voa/00/voa_0061   0    5              the    DT             (NP*             -    -   -   -   *         *   (ARG2*            *        *      -
bn/voa/00/voa_0061   0    6             main    JJ                *             -    -   -   -   *         *        *            *        *      -
bn/voa/00/voa_0061   0    7          therapy    NN              *)))            -    -   -   -   *         *        *)           *        *      -
bn/voa/00/voa_0061   0    8              but    CC                *             -    -   -   -   *         *        *            *        *      -
bn/voa/00/voa_0061   0    9               it   PRP           (S(NP*)            -    -   -   -   *         *        *       (ARG0*)       *    (11)
bn/voa/00/voa_0061   0   10            loses   VBZ             (VP*           lose  02   5   -   *         *        *          (V*)       *      -
bn/voa/00/voa_0061   0   11    effectiveness    NN             (NP*)            -    -   -   -   *         *        *       (ARG1*)       *      -
bn/voa/00/voa_0061   0   12               as    IN           (SBAR*             -    -   -   -   *         *        *   (ARGM-TMP*        *      -
bn/voa/00/voa_0061   0   13              the    DT           (S(NP*             -    -   -   -   *         *        *            *   (ARG1*    (14
bn/voa/00/voa_0061   0   14          disease    NN                *)            -    -   -   -   *         *        *            *        *)    14)
bn/voa/00/voa_0061   0   15       progresses   VBZ         (VP*)))))      progress  01   1   -   *         *        *            *)     (V*)     -
bn/voa/00/voa_0061   0   16                .     .               *))            -    -   -   -   *         *        *            *        *      -

bn/voa/00/voa_0061   0    0              The    DT  (TOP(S(S(NP*            -    -   -   -   *   (ARG1*            *        *        *         *    (12
bn/voa/00/voa_0061   0    1             next    JJ             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0    2             step    NN             *)         step   -   1   -   *        *)           *        *        *         *     12)
bn/voa/00/voa_0061   0    3               is   VBZ          (VP*            be  01   -   -   *      (V*)           *        *        *         *      -
bn/voa/00/voa_0061   0    4    transplanting   VBG        (S(VP*    transplant  01   1   -   *   (ARG2*          (V*)       *        *         *      -
bn/voa/00/voa_0061   0    5            nerve    JJ       (NP(NP*            -    -   -   -   *        *       (ARG1*        *        *         *      -
bn/voa/00/voa_0061   0    6           tissue    NN             *)           -    -   -   -   *        *            *)       *        *         *      -
bn/voa/00/voa_0061   0    7             from    IN          (PP*            -    -   -   -   *        *       (ARG3*        *        *         *      -
bn/voa/00/voa_0061   0    8                a    DT          (NP*            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0    9            fetus    NN           *)))           -    -   -   -   *        *            *)       *        *         *      -
bn/voa/00/voa_0061   0   10               to    TO        (S(VP*            -    -   -   -   *        *   (ARGM-PRP*        *        *         *      -
bn/voa/00/voa_0061   0   11          replace    VB          (VP*       replace  01   1   -   *        *            *      (V*)       *         *      -
bn/voa/00/voa_0061   0   12              the    DT          (NP*            -    -   -   -   *        *            *   (ARG1*        *         *      -
bn/voa/00/voa_0061   0   13             lost   VBN             *          lose  02   -   -   *        *            *        *      (V*)        *      -
bn/voa/00/voa_0061   0   14         dopamine    NN             *            -    -   -   -   *        *            *        *   (ARG1*         *      -
bn/voa/00/voa_0061   0   15          neurons   NNS      *))))))))           -    -   -   -   *        *)           *)       *)       *)        *      -
bn/voa/00/voa_0061   0   16                ,     ,             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0   17              but    CC             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0   18             that    DT        (S(NP*)           -    -   -   -   *        *            *        *        *    (ARG1*)   (12)
bn/voa/00/voa_0061   0   19               is   VBZ          (VP*            be  01   1   -   *        *            *        *        *       (V*)     -
bn/voa/00/voa_0061   0   20                a    DT          (NP*            -    -   -   -   *        *            *        *        *    (ARG2*      -
bn/voa/00/voa_0061   0   21           costly    JJ             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0   22                ,     ,             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0   23            risky    JJ             *            -    -   -   -   *        *            *        *        *         *      -
bn/voa/00/voa_0061   0   24          surgery    NN           *)))           -    -   -   -   *        *            *        *        *         *)     -
bn/voa/00/voa_0061   0   25                .     .            *))           -    -   -   -   *        *            *        *        *         *      -

bn/voa/00/voa_0061   0    0             Now     RB   (TOP(S(ADVP*)         -    -   -   -            *      *    (ARGM-TMP*)            *            *      -
bn/voa/00/voa_0061   0    1               a     DT           (NP*          -    -   -   -            *      *        (ARG0*             *            *     (4
bn/voa/00/voa_0061   0    2              US    NNP          (NML*          -    -   -   -         (GPE)     *             *             *            *      -
bn/voa/00/voa_0061   0    3              -    HYPH              *          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0    4           Swiss    NNP              *          -    -   -   -        (NORP)     *             *             *            *      -
bn/voa/00/voa_0061   0    5              -    HYPH              *          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0    6          French    NNP              *)         -    -   -   -        (NORP)     *             *             *            *      -
bn/voa/00/voa_0061   0    7           group     NN              *)      group   -   1   -            *      *             *)            *            *      4)
bn/voa/00/voa_0061   0    8             has    VBZ           (VP*        have  01   -   -            *    (V*)            *             *            *      -
bn/voa/00/voa_0061   0    9    successfully     RB         (ADVP*)         -    -   -   -            *      *    (ARGM-MNR*)            *            *      -
bn/voa/00/voa_0061   0   10          tested    VBN           (VP*        test  01   1   -            *      *           (V*)            *            *      -
bn/voa/00/voa_0061   0   11               a     DT        (NP(NP*          -    -   -   -            *      *        (ARG1*             *            *     (6
bn/voa/00/voa_0061   0   12           third     JJ              *          -    -   -   -     (ORDINAL)     *             *    (ARGM-TMP*)           *      -
bn/voa/00/voa_0061   0   13        approach     NN             *))   approach  02   3   -            *      *             *)          (V*)           *      6)
bn/voa/00/voa_0061   0   14              in     IN           (PP*          -    -   -   -            *      *    (ARGM-LOC*             *            *      -
bn/voa/00/voa_0061   0   15         monkeys     NN          (NP*))         -    -   -   -            *      *             *)            *            *    (20)
bn/voa/00/voa_0061   0   16               ,      ,              *          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   17             one     CD        (NP(NP*)         -    -   -   -    (CARDINAL)     *      (C-ARG1*    (ARGM-ADJ*            *     (6
bn/voa/00/voa_0061   0   18            that    WDT    (SBAR(WHNP*)         -    -   -   -            *      *             *             *       (ARG0*)     -
bn/voa/00/voa_0061   0   19        delivers    VBZ         (S(VP*     deliver  01   5   -            *      *             *             *          (V*)     -
bn/voa/00/voa_0061   0   20             the     DT        (NP(NP*          -    -   -   -            *      *             *             *       (ARG1*      -
bn/voa/00/voa_0061   0   21           seeds    NNS              *)         -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   22              of     IN           (PP*          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   23               a     DT           (NP*          -    -   -   -            *      *             *             *            *    (10
bn/voa/00/voa_0061   0   24        dopamine     NN          (NML*          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   25          neuron     NN              *)         -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   26     nourishment     NN              *          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   27         protein     NN            *)))         -    -   -   -            *      *             *             *            *)    10)
bn/voa/00/voa_0061   0   28        directly     RB      (PP(ADVP*)         -    -   -   -            *      *             *             *       (ARG2*      -
bn/voa/00/voa_0061   0   29              to     IN              *          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   30             the     DT           (NP*          -    -   -   -            *      *             *             *            *      -
bn/voa/00/voa_0061   0   31           brain     NN             *))         -    -   -   -            *      *             *             *            *)     -
bn/voa/00/voa_0061   0   32              by     IN           (PP*          -    -   -   -            *      *             *             *   (ARGM-MNR*      -
bn/voa/00/voa_0061   0   33       injection     NN    (NP*))))))))         -    -   -   -            *      *             *)            *)           *)     6)
bn/voa/00/voa_0061   0   34               .      .             *))         -    -   -   -            *      *             *             *            *      -

bn/voa/00/voa_0061   0    0            It    PRP   (TOP(S(NP*)      -    -   -   -   *       (ARG0*)           *    (10)
bn/voa/00/voa_0061   0    1         works    VBZ         (VP*     work  01   2   -   *          (V*)           *      -
bn/voa/00/voa_0061   0    2            as     IN         (PP*       -    -   -   -   *       (ARG1*            *      -
bn/voa/00/voa_0061   0    3             a     DT      (NP(NP*       -    -   -   -   *            *            *      -
bn/voa/00/voa_0061   0    4    protectant     NN            *)      -    -   -   -   *            *            *      -
bn/voa/00/voa_0061   0    5            of     IN         (PP*       -    -   -   -   *            *            *      -
bn/voa/00/voa_0061   0    6           the     DT         (NP*       -    -   -   -   *            *            *      -
bn/voa/00/voa_0061   0    7          cell     NN         *))))    cell   -   1   -   *            *)           *      -
bn/voa/00/voa_0061   0    8            so     IN       (SBAR*       -    -   -   -   *   (ARGM-PRP*            *      -
bn/voa/00/voa_0061   0    9            to     TO       (S(VP*       -    -   -   -   *            *            *      -
bn/voa/00/voa_0061   0   10          stop     VB         (VP*     stop  01   1   -   *            *          (V*)     -
bn/voa/00/voa_0061   0   11           the     DT         (NP*       -    -   -   -   *            *       (ARG1*    (14
bn/voa/00/voa_0061   0   12       disease     NN            *)      -    -   -   -   *            *            *)    14)
bn/voa/00/voa_0061   0   13            in     IN         (PP*       -    -   -   -   *            *   (ARGM-LOC*      -
bn/voa/00/voa_0061   0   14           its   PRP$         (NP*       -    -   -   -   *            *            *    (14)
bn/voa/00/voa_0061   0   15        tracks    NNS      *)))))))   track   -   1   -   *            *)           *)     -
bn/voa/00/voa_0061   0   16             .      .           *))      -    -   -   -   *            *            *      -

bn/voa/00/voa_0061   0    0            This     DT   (TOP(S(NP*)       -    -   -   -          *    (ARG1*)   (15)
bn/voa/00/voa_0061   0    1              is    VBZ         (VP*        be  01   2   -          *       (V*)     -
bn/voa/00/voa_0061   0    2           study     NN  (NP(NP(NML*     study   -   3   -          *    (ARG2*      -
bn/voa/00/voa_0061   0    3          leader     NN            *)   leader   -   1   -          *         *      -
bn/voa/00/voa_0061   0    4         Jeffery    NNP            *        -    -   -   -   (PERSON*         *      -
bn/voa/00/voa_0061   0    5         Codover    NNP            *)       -    -   -   -          *)        *      -
bn/voa/00/voa_0061   0    6              of     IN         (PP*        -    -   -   -          *         *      -
bn/voa/00/voa_0061   0    7            Rush    NNP      (NP(NP*        -    -   -   -      (ORG*         *      -
bn/voa/00/voa_0061   0    8    Presbyterian    NNP            *        -    -   -   -          *         *      -
bn/voa/00/voa_0061   0    9             St.    NNP        (NML*        -    -   -   -          *         *      -
bn/voa/00/voa_0061   0   10           Lukes   NNPS            *)       -    -   -   -          *         *      -
bn/voa/00/voa_0061   0   11         Medical    NNP            *        -    -   -   -          *         *      -
bn/voa/00/voa_0061   0   12          Center    NNP            *)       -    -   -   -          *)        *      -
bn/voa/00/voa_0061   0   13              in     IN         (PP*        -    -   -   -          *         *      -
bn/voa/00/voa_0061   0   14         Chicago    NNP    (NP*))))))       -    -   -   -       (GPE)        *)     -
bn/voa/00/voa_0061   0   15               .      .           *))       -    -   -   -          *         *      -

bn/voa/00/voa_0061   0    0            The     DT  (TOP(S(NP(NP*           -    -   -   -   *        *   (ARG1*      *    (ARG1*       (10
bn/voa/00/voa_0061   0    1    stimulating    VBG              *    stimulate  01   1   -   *      (V*)       *      *         *         -
bn/voa/00/voa_0061   0    2          brain     NN              *           -    -   -   -   *   (ARG0*        *      *         *         -
bn/voa/00/voa_0061   0    3        protein     NN              *)          -    -   -   -   *        *)       *)     *         *         -
bn/voa/00/voa_0061   0    4            his   PRP$    (SBAR(S(NP*           -    -   -   -   *        *   (ARG0*      *         *    (4|(15)
bn/voa/00/voa_0061   0    5           team     NN              *)        team   -   1   -   *        *        *)     *         *         4)
bn/voa/00/voa_0061   0    6           used    VBD        (VP*))))         use  01   1   -   *        *      (V*)     *         *)       10)
bn/voa/00/voa_0061   0    7             is    VBZ           (VP*           be  03   -   -   *        *        *    (V*)        *         -
bn/voa/00/voa_0061   0    8         called    VBN           (VP*         call  01   5   -   *        *        *      *       (V*)        -
bn/voa/00/voa_0061   0    9           GDNF    NNP      (S(NP*))))          -    -   -   -   *        *        *      *    (ARG2*)        -
bn/voa/00/voa_0061   0   10              .      .             *))          -    -   -   -   *        *        *      *         *         -

bn/voa/00/voa_0061   0    0    Previous    JJ      (TOP(S(S(NP*         -    -   -   -   *    (ARGM-TMP*)     *   (ARG0*         *      *      *         *      -
bn/voa/00/voa_0061   0    1     studies   NNS                 *)     study  01   3   -   *           (V*)     *        *)        *      *      *         *      -
bn/voa/00/voa_0061   0    2        have   VBP              (VP*       have  01   -   -   *             *    (V*)       *         *      *      *         *      -
bn/voa/00/voa_0061   0    3       shown   VBN              (VP*       show  01   1   -   *             *      *      (V*)        *      *      *         *      -
bn/voa/00/voa_0061   0    4        that    IN            (SBAR*         -    -   -   -   *             *      *   (ARG1*         *      *      *         *      -
bn/voa/00/voa_0061   0    5        GDNF   NNP            (S(NP*)        -    -   -   -   *             *      *        *    (ARG0*)     *      *         *    (10)
bn/voa/00/voa_0061   0    6       keeps   VBZ              (VP*       keep  02   1   -   *             *      *        *       (V*)     *      *         *      -
bn/voa/00/voa_0061   0    7    dopamine    NN              (NP*         -    -   -   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0    8       cells   NNS                 *)      cell   -   1   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0    9     healthy    JJ   (S(ADJP*))))))))        -    -   -   -   *             *      *        *)   (ARG1*)     *      *         *      -
bn/voa/00/voa_0061   0   10         but    CC                 *         -    -   -   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0   11         the    DT            (S(NP*         -    -   -   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0   12     problem    NN                 *)   problem   -   1   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0   13         has   VBZ              (VP*       have  01   -   -   *             *      *        *         *    (V*)     *         *      -
bn/voa/00/voa_0061   0   14        been   VBN              (VP*         be  03   -   -   *             *      *        *         *      *    (V*)        *      -
bn/voa/00/voa_0061   0   15     getting   VBG              (VP*        get  05   3   -   *             *      *        *         *      *      *       (V*)     -
bn/voa/00/voa_0061   0   16          it   PRP              (NP*)        -    -   -   -   *             *      *        *         *      *      *    (ARG1*)   (10)
bn/voa/00/voa_0061   0   17          to    IN              (PP*         -    -   -   -   *             *      *        *         *      *      *    (ARG2*      -
bn/voa/00/voa_0061   0   18         the    DT              (NP*         -    -   -   -   *             *      *        *         *      *      *         *      -
bn/voa/00/voa_0061   0   19       brain    NN            *))))))        -    -   -   -   *             *      *        *         *      *      *         *)     -
bn/voa/00/voa_0061   0   20           .     .                *))        -    -   -   -   *             *      *        *         *      *      *         *      -

bn/voa/00/voa_0061   0    0           As    IN   (TOP(S(PP*         -    -   -   -   *   (ARGM-ADV*            *         *        *        *     -
bn/voa/00/voa_0061   0    1            a    DT         (NP*         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0    2      defense    NN           *))   defense   -   2   -   *            *)           *         *        *        *     -
bn/voa/00/voa_0061   0    3            ,     ,            *         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0    4          the    DT      (NP(NP*         -    -   -   -   *       (ARG0*            *         *        *        *     -
bn/voa/00/voa_0061   0    5        brain    NN            *         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0    6           's   POS            *)        -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0    7        blood    NN            *         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0    8      vessels   NNS            *)        -    -   -   -   *            *)           *         *        *        *     -
bn/voa/00/voa_0061   0    9      prevent   VBP         (VP*    prevent  01   1   -   *          (V*)           *         *        *        *    (1)
bn/voa/00/voa_0061   0   10         most   JJS         (NP*         -    -   -   -   *       (ARG1*       (ARG0*         *        *        *     -
bn/voa/00/voa_0061   0   11    compounds   NNS            *)        -    -   -   -   *            *)           *)        *        *        *     -
bn/voa/00/voa_0061   0   12         from    IN         (PP*         -    -   -   -   *       (ARG2*            *         *        *        *     -
bn/voa/00/voa_0061   0   13     entering   VBG       (S(VP*      enter  01   1   -   *            *          (V*)        *        *        *     -
bn/voa/00/voa_0061   0   14         from    IN         (PP*         -    -   -   -   *            *   (ARGM-DIR*         *        *        *     -
bn/voa/00/voa_0061   0   15          the    DT         (NP*         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0   16        blood    NN            *         -    -   -   -   *            *            *    (ARG1*)       *        *     -
bn/voa/00/voa_0061   0   17       stream    NN        *)))))    stream  01   1   -   *            *)           *)      (V*)       *        *     -
bn/voa/00/voa_0061   0   18       making   VBG       (S(VP*       make  02   3   -   *   (ARGM-ADV*            *         *      (V*)       *     -
bn/voa/00/voa_0061   0   19           it   PRP   (S(NP(NP*))        -    -   -   -   *            *            *         *   (ARG1*        *     -
bn/voa/00/voa_0061   0   20    difficult    JJ       (ADJP*)        -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0   21           to    TO       (S(VP*         -    -   -   -   *            *            *         *        *        *     -
bn/voa/00/voa_0061   0   22       design    VB         (VP*     design  01   1   -   *            *            *         *        *      (V*)    -
bn/voa/00/voa_0061   0   23            a    DT         (NP*         -    -   -   -   *            *            *         *        *   (ARG1*     -
bn/voa/00/voa_0061   0   24    Parkinson   NNP     (NML(NP*         -    -   -   -   *            *            *         *        *        *   (14
bn/voa/00/voa_0061   0   25           's   POS           *))        -    -   -   -   *            *            *         *        *        *    14)
bn/voa/00/voa_0061   0   26         drug    NN     *))))))))        -    -   -   -   *            *)           *         *        *)       *)    -
bn/voa/00/voa_0061   0   27            .     .           *))        -    -   -   -   *            *            *         *        *        *     -

bn/voa/00/voa_0061   0    0          To    TO  (TOP(S(S(VP*          -    -   -   -          *         *   (R-ARG0*         *         -
bn/voa/00/voa_0061   0    1    overcome    VB          (VP*    overcome  01   1   -          *       (V*)         *         *         -
bn/voa/00/voa_0061   0    2        this    DT       (NP*))))         -    -   -   -          *    (ARG1*)         *)        *        (1)
bn/voa/00/voa_0061   0    3           ,     ,             *          -    -   -   -          *         *          *         *         -
bn/voa/00/voa_0061   0    4         Mr.   NNP       (NP(NP*          -    -   -   -          *    (ARG0*     (ARG0*         *    (4|(15
bn/voa/00/voa_0061   0    5     Codover   NNP             *          -    -   -   -    (PERSON)        *          *         *         -
bn/voa/00/voa_0061   0    6          's   POS             *)         -    -   -   -          *         *          *         *        15)
bn/voa/00/voa_0061   0    7        team    NN             *)       team   -   1   -          *         *)         *)        *         4)
bn/voa/00/voa_0061   0    8    injected   VBD          (VP*      inject  01   1   -          *         *        (V*)        *         -
bn/voa/00/voa_0061   0    9           a    DT       (NP(NP*          -    -   -   -          *         *     (ARG1*         *        (8
bn/voa/00/voa_0061   0   10        gene    NN             *)         -    -   -   -          *         *          *         *         -
bn/voa/00/voa_0061   0   11          to    TO   (SBAR(S(VP*          -    -   -   -          *         *          *         *         -
bn/voa/00/voa_0061   0   12        make    VB          (VP*        make  01   2   -          *         *          *       (V*)        -
bn/voa/00/voa_0061   0   13        GDNF   NNP     (NP*))))))         -    -   -   -          *         *          *)   (ARG1*)   (10)|8)
bn/voa/00/voa_0061   0   14       right    RB     (PP(ADVP*)         -    -   -   -          *         *     (ARG2*         *         -
bn/voa/00/voa_0061   0   15        into    IN             *          -    -   -   -          *         *          *         *         -
bn/voa/00/voa_0061   0   16         the    DT       (NP(NP*          -    -   -   -          *         *          *         *       (20
bn/voa/00/voa_0061   0   17      monkey    NN             *          -    -   -   -          *         *          *         *         -
bn/voa/00/voa_0061   0   18          's   POS             *)         -    -   -   -          *         *          *         *        20)
bn/voa/00/voa_0061   0   19      brains   NNS           *)))         -    -   -   -          *         *          *)        *         -
bn/voa/00/voa_0061   0   20           .     .            *))         -    -   -   -          *         *          *         *         -

bn/voa/00/voa_0061   0    0             To     TO  (TOP(S(S(VP*           -    -   -   -       *        *   (ARGM-PRP*        *         *      -
bn/voa/00/voa_0061   0    1      transport     VB          (VP*    transport  01   1   -       *      (V*)           *        *         *      -
bn/voa/00/voa_0061   0    2            the     DT          (NP*           -    -   -   -       *   (ARG1*            *        *         *     (8
bn/voa/00/voa_0061   0    3           gene     NN          *))))          -    -   -   -       *        *)           *)       *         *      8)
bn/voa/00/voa_0061   0    4              ,      ,             *           -    -   -   -       *        *            *        *         *      -
bn/voa/00/voa_0061   0    5      Louisiane    NNP      (NP(NML*           -    -   -   -   (ORG*        *       (ARG0*        *         *    (13
bn/voa/00/voa_0061   0    6     University    NNP             *)          -    -   -   -       *)       *            *        *         *      -
bn/voa/00/voa_0061   0    7    researchers    NNS             *)          -    -   -   -       *        *            *)       *         *     13)
bn/voa/00/voa_0061   0    8        devised    VBD          (VP*       devise  01   1   -       *        *          (V*)       *         *      -
bn/voa/00/voa_0061   0    9             an     DT       (NP(NP*           -    -   -   -       *        *       (ARG1*   (ARG1*         *    (17
bn/voa/00/voa_0061   0   10            HIV    NNP             *           -    -   -   -       *        *            *        *         *      -
bn/voa/00/voa_0061   0   11          virus     NN             *)          -    -   -   -       *        *            *        *)        *      -
bn/voa/00/voa_0061   0   12       stripped    VBN          (VP*        strip  01   1   -       *        *            *      (V*)        *      -
bn/voa/00/voa_0061   0   13             of     IN          (PP*           -    -   -   -       *        *            *   (ARG2*         *      -
bn/voa/00/voa_0061   0   14            its   PRP$          (NP*           -    -   -   -       *        *            *        *         *    (17)
bn/voa/00/voa_0061   0   15      infecting    VBG             *       infect  01   -   -       *        *            *        *       (V*)     -
bn/voa/00/voa_0061   0   16      machinery     NN         *)))))          -    -   -   -       *        *            *)       *)   (ARG0*)    17)
bn/voa/00/voa_0061   0   17              .      .            *))          -    -   -   -       *        *            *        *         *      -

bn/voa/00/voa_0061   0    0           When   WRB   (TOP(S(SBAR(WHADVP*)        -    -   -   -   *    (ARGM-TMP*)        *    (ARGM-TMP*        *        *            *      -
bn/voa/00/voa_0061   0    1           they   PRP                (S(NP*)        -    -   -   -   *        (ARG0*)        *             *        *        *            *    (13)
bn/voa/00/voa_0061   0    2       injected   VBD                  (VP*     inject  01   1   -   *           (V*)        *             *        *        *            *      -
bn/voa/00/voa_0061   0    3            the    DT                  (NP*         -    -   -   -   *        (ARG1*         *             *        *        *            *    (17
bn/voa/00/voa_0061   0    4        altered    JJ                     *         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0    5          virus    NN                     *)        -    -   -   -   *             *)        *             *        *        *            *     17)
bn/voa/00/voa_0061   0    6           into    IN                  (PP*         -    -   -   -   *        (ARG2*         *             *        *        *            *      -
bn/voa/00/voa_0061   0    7         brains   NNS               (NP(NP*)        -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0    8             of    IN                  (PP*         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0    9          aging   VBG               (NP(NP*        age  01   -   -   *             *       (V*)            *        *        *            *    (22
bn/voa/00/voa_0061   0   10        animals   NNS                     *)        -    -   -   -   *             *    (ARG1*)            *        *        *            *      -
bn/voa/00/voa_0061   0   11           with    IN                  (PP*         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   12          early    JJ                  (NP*         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   13      Parkinson   NNP                  (NP*         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   14             's   POS            *))))))))))        -    -   -   -   *             *)        *             *)       *        *            *     22)
bn/voa/00/voa_0061   0   15             it   PRP                  (NP*)        -    -   -   -   *             *         *        (ARG0*)       *        *            *    (17)
bn/voa/00/voa_0061   0   16       conveyed   VBD                  (VP*     convey  01   2   -   *             *         *           (V*)       *        *            *      -
bn/voa/00/voa_0061   0   17            the    DT                  (NP*         -    -   -   -   *             *         *        (ARG1*        *        *            *     (8
bn/voa/00/voa_0061   0   18       attached   VBN                     *     attach  01   -   -   *             *         *             *      (V*)       *            *      -
bn/voa/00/voa_0061   0   19           GDNF   NNP                     *         -    -   -   -   *             *         *             *   (ARG1*        *            *    (10)
bn/voa/00/voa_0061   0   20           gene    NN                     *)        -    -   -   -   *             *         *             *)       *)       *            *      8)
bn/voa/00/voa_0061   0   21    efficiently    RB                (ADVP*)        -    -   -   -   *             *         *    (ARGM-MNR*)       *        *            *      -
bn/voa/00/voa_0061   0   22              ,     ,                     *         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   23        causing   VBG                (S(VP*      cause  01   1   -   *             *         *    (ARGM-PRD*        *      (V*)           *      -
bn/voa/00/voa_0061   0   24       dopamine    NN                (S(NP*         -    -   -   -   *             *         *             *        *   (ARG1*       (ARG0*      -
bn/voa/00/voa_0061   0   25          cells   NNS                     *)      cell   -   1   -   *             *         *             *        *        *            *)     -
bn/voa/00/voa_0061   0   26             to    TO                  (VP*         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   27        produce    VB                  (VP*    produce  01   1   -   *             *         *             *        *        *          (V*)     -
bn/voa/00/voa_0061   0   28            the    DT                  (NP*         -    -   -   -   *             *         *             *        *        *       (ARG1*    (10
bn/voa/00/voa_0061   0   29         rescue    NN                     *         -    -   -   -   *             *         *             *        *        *            *      -
bn/voa/00/voa_0061   0   30        protein    NN                     *)        -    -   -   -   *             *         *             *        *        *            *)    10)
bn/voa/00/voa_0061   0   31             on    IN                  (PP*         -    -   -   -   *             *         *             *        *        *   (ARGM-LOC*      -
bn/voa/00/voa_0061   0   32           site    NN           (NP*))))))))      site   -   2   -   *             *         *             *)       *        *)           *)     -
bn/voa/00/voa_0061   0   33              .     .                    *))        -    -   -   -   *             *         *             *        *        *            *      -

bn/voa/00/voa_0061   0    0            When   WRB   (TOP(S(SBAR(WHADVP*)        -    -   -   -   *    (ARGM-TMP*)        *   (ARGM-TMP*             *      *            *         *         *         -
bn/voa/00/voa_0061   0    1              we   PRP                (S(NP*)        -    -   -   -   *        (ARG0*)        *            *             *      *            *         *         *       (13)
bn/voa/00/voa_0061   0    2       delivered   VBD                  (VP*    deliver  01   5   -   *           (V*)        *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0    3            GDNF   NNP                  (NP*)        -    -   -   -   *        (ARG1*)        *            *             *      *            *         *         *       (10)
bn/voa/00/voa_0061   0    4             via    IN                  (PP*         -    -   -   -   *    (ARGM-MNR*         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0    5            gene    NN                  (NP*         -    -   -   -   *             *         *            *             *      *            *         *         *        (2
bn/voa/00/voa_0061   0    6         therapy    NN                    *))        -    -   -   -   *             *)        *            *             *      *            *         *         *         2)
bn/voa/00/voa_0061   0    7              in    IN                  (PP*         -    -   -   -   *    (ARGM-LOC*         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0    8           these    DT                  (NP*         -    -   -   -   *             *         *            *             *      *            *         *         *       (22
bn/voa/00/voa_0061   0    9            aged   VBN                     *        age  01   -   -   *             *       (V*)           *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   10         monkeys   NNS                 *)))))        -    -   -   -   *             *)   (ARG1*)           *)            *      *            *         *         *        22)
bn/voa/00/voa_0061   0   11              we   PRP                  (NP*)        -    -   -   -   *             *         *       (ARG1*)       (ARG0*)     *            *         *         *       (13)
bn/voa/00/voa_0061   0   12            were   VBD                  (VP*         be  01   -   -   *             *         *          (V*)            *      *            *         *         *         -
bn/voa/00/voa_0061   0   13            able    JJ                (ADJP*         -    -   -   -   *             *         *       (ARG2*             *      *            *         *         *         -
bn/voa/00/voa_0061   0   14              to    TO                (S(VP*         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   15      completely    RB                (ADVP*)        -    -   -   -   *             *         *            *    (ARGM-EXT*)     *            *         *         *         -
bn/voa/00/voa_0061   0   16         reverse    VB                  (VP*    reverse  01   1   -   *             *         *            *           (V*)     *            *         *         *         -
bn/voa/00/voa_0061   0   17             all   PDT            (NP(NP(NP*         -    -   -   -   *             *         *            *        (ARG1*      *       (ARG1*         *         *       (18
bn/voa/00/voa_0061   0   18             the    DT                     *         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   19        cellular    JJ                     *         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   20         changes   NNS                     *)    change   -   1   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   21               ,     ,                     *         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   22    degenerative    JJ                  (NP*         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   23         changes   NNS                    *))    change   -   1   -   *             *         *            *             *      *            *)        *         *         -
bn/voa/00/voa_0061   0   24            that   WDT           (SBAR(WHNP*)        -    -   -   -   *             *         *            *             *      *     (R-ARG1*)        *         *         -
bn/voa/00/voa_0061   0   25             are   VBP                (S(VP*         be  03   -   -   *             *         *            *             *    (V*)           *         *         *         -
bn/voa/00/voa_0061   0   26            seen   VBN                  (VP*        see  01   3   -   *             *         *            *             *      *          (V*)        *         *         -
bn/voa/00/voa_0061   0   27              in    IN                  (PP*         -    -   -   -   *             *         *            *             *      *   (ARGM-LOC*         *         *         -
bn/voa/00/voa_0061   0   28            aged   VBN                  (NP*        age  01   -   -   *             *         *            *             *      *            *       (V*)        *         -
bn/voa/00/voa_0061   0   29         monkeys   NNS                *))))))        -    -   -   -   *             *         *            *             *      *            *)   (ARG1*)        *         -
bn/voa/00/voa_0061   0   30              as    IN                (SBAR*         -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   31            they   PRP                (S(NP*)        -    -   -   -   *             *         *            *             *      *            *         *    (ARG1*)      (18)
bn/voa/00/voa_0061   0   32          relate   VBP                  (VP*     relate  01   2   -   *             *         *            *             *      *            *         *       (V*)        -
bn/voa/00/voa_0061   0   33              to    IN                  (PP*         -    -   -   -   *             *         *            *             *      *            *         *    (ARG2*         -
bn/voa/00/voa_0061   0   34       Parkinson   NNP               (NP(NP*         -    -   -   -   *             *         *            *             *      *            *         *         *       (14
bn/voa/00/voa_0061   0   35              's   POS                     *)        -    -   -   -   *             *         *            *             *      *            *         *         *         -
bn/voa/00/voa_0061   0   36         Disease   NNP           *)))))))))))        -    -   -   -   *             *         *            *)            *)     *            *         *         *)   18)|14)
bn/voa/00/voa_0061   0   37               .     .                    *))        -    -   -   -   *             *         *            *             *      *            *         *         *         -

bn/voa/00/voa_0061   0    0            The    DT      (TOP(S(NP*          -    -   -   -               *       (ARG0*             *             *      *              *   (13
bn/voa/00/voa_0061   0    1    researchers   NNS               *)         -    -   -   -               *            *)            *             *      *              *    13)
bn/voa/00/voa_0061   0    2         report   VBP            (VP*      report  01   1   -               *          (V*)            *             *      *              *     -
bn/voa/00/voa_0061   0    3             in    IN            (PP*          -    -   -   -               *   (ARGM-LOC*             *             *      *              *     -
bn/voa/00/voa_0061   0    4            the    DT         (NP(NP*          -    -   -   -               *            *             *             *      *              *     -
bn/voa/00/voa_0061   0    5        journal    NN               *)         -    -   -   -               *            *             *             *      *              *     -
bn/voa/00/voa_0061   0    6        Science   NNP          (NP*)))         -    -   -   -    (WORK_OF_ART)           *)            *             *      *              *     -
bn/voa/00/voa_0061   0    7           that    IN          (SBAR*          -    -   -   -               *       (ARG1*             *             *      *              *     -
bn/voa/00/voa_0061   0    8            the    DT          (S(NP*          -    -   -   -               *            *        (ARG0*             *      *              *    (2
bn/voa/00/voa_0061   0    9           gene    NN               *          -    -   -   -               *            *             *             *      *              *     -
bn/voa/00/voa_0061   0   10        therapy    NN               *)         -    -   -   -               *            *             *)            *      *              *     2)
bn/voa/00/voa_0061   0   11           also    RB          (ADVP*)         -    -   -   -               *            *    (ARGM-DIS*)            *      *              *     -
bn/voa/00/voa_0061   0   12       restored   VBD            (VP*     restore  01   1   -               *            *           (V*)            *      *              *     -
bn/voa/00/voa_0061   0   13    coordinated    JJ            (NP*          -    -   -   -               *            *        (ARG1*    (ARGM-MNR*)     *              *     -
bn/voa/00/voa_0061   0   14       movement    NN               *)   movement  01   1   -               *            *             *)          (V*)     *              *     -
bn/voa/00/voa_0061   0   15             in    IN            (PP*          -    -   -   -               *            *        (ARG2*             *      *              *     -
bn/voa/00/voa_0061   0   16          young    JJ         (NP(NP*          -    -   -   -               *            *             *             *      *     (ARGM-LOC*     -
bn/voa/00/voa_0061   0   17        monkeys   NNS               *)         -    -   -   -               *            *             *             *      *              *)    -
bn/voa/00/voa_0061   0   18             in    IN     (SBAR(WHPP*          -    -   -   -               *            *             *             *      *   (R-ARGM-LOC*     -
bn/voa/00/voa_0061   0   19          which   WDT         (WHNP*))         -    -   -   -               *            *             *             *      *              *)    -
bn/voa/00/voa_0061   0   20      Parkinson   NNP       (S(NP(NP*          -    -   -   -               *            *             *             *      *         (ARG1*   (14
bn/voa/00/voa_0061   0   21             's   POS              *))         -    -   -   -               *            *             *             *      *              *)   14)
bn/voa/00/voa_0061   0   22            was   VBD            (VP*          be  03   -   -               *            *             *             *    (V*)             *     -
bn/voa/00/voa_0061   0   23     chemically    RB          (ADVP*)         -    -   -   -               *            *             *             *      *     (ARGM-MNR*)    -
bn/voa/00/voa_0061   0   24        induced   VBN   (VP*))))))))))     induce  01   1   -               *            *)            *)            *      *            (V*)    -
bn/voa/00/voa_0061   0   25              .     .              *))         -    -   -   -               *            *             *             *      *              *     -

bn/voa/00/voa_0061   0    0            The     DT   (TOP(S(NP(NP*           -    -   -   -   *       (ARG1*        (ARG1*             *      -
bn/voa/00/voa_0061   0    1       benefits    NNS               *)     benefit   -   1   -   *            *             *             *      -
bn/voa/00/voa_0061   0    2             of     IN            (PP*           -    -   -   -   *            *             *             *      -
bn/voa/00/voa_0061   0    3            the     DT            (NP*           -    -   -   -   *            *             *             *     (2
bn/voa/00/voa_0061   0    4      treatment     NN             *)))   treatment   -   1   -   *            *)            *)            *      2)
bn/voa/00/voa_0061   0    5         appear    VBP            (VP*       appear  02   1   -   *          (V*)            *             *      -
bn/voa/00/voa_0061   0    6      permanent     JJ   (S(ADJP(ADJP*)          -    -   -   -   *     (C-ARG1*             *             *      -
bn/voa/00/voa_0061   0    7             or     CC               *           -    -   -   -   *            *             *             *      -
bn/voa/00/voa_0061   0    8             at     IN     (ADJP(ADVP*           -    -   -   -   *            *    (ARGM-ADV*             *      -
bn/voa/00/voa_0061   0    9          least    JJS               *)          -    -   -   -   *            *             *)            *      -
bn/voa/00/voa_0061   0   10           very     RB               *           -    -   -   -   *            *             *             *      -
bn/voa/00/voa_0061   0   11           long     RB               *           -    -   -   -   *            *    (ARGM-EXT*)            *      -
bn/voa/00/voa_0061   0   12             -    HYPH               *           -    -   -   -   *            *             *             *      -
bn/voa/00/voa_0061   0   13        lasting    VBG             *)))        last  01   -   -   *            *)          (V*)            *      -
bn/voa/00/voa_0061   0   14             as     IN          (SBAR*           -    -   -   -   *   (ARGM-CAU*             *             *      -
bn/voa/00/voa_0061   0   15           GDNF    NNP          (S(NP*           -    -   -   -   *            *             *        (ARG0*    (10)
bn/voa/00/voa_0061   0   16          genes    NNS               *)          -    -   -   -   *            *             *             *)     -
bn/voa/00/voa_0061   0   17    continually     RB          (ADVP*)          -    -   -   -   *            *             *    (ARGM-MNR*)     -
bn/voa/00/voa_0061   0   18        produce    VBP            (VP*      produce  01   1   -   *            *             *           (V*)     -
bn/voa/00/voa_0061   0   19            the     DT            (NP*           -    -   -   -   *            *             *        (ARG1*    (10
bn/voa/00/voa_0061   0   20         rescue     NN               *           -    -   -   -   *            *             *             *      -
bn/voa/00/voa_0061   0   21        protein     NN           *)))))          -    -   -   -   *            *)            *             *)    10)
bn/voa/00/voa_0061   0   22              .      .              *))          -    -   -   -   *            *             *             *      -

bn/voa/00/voa_0061   0    0           Mr.   NNP    (TOP(S(NP*        -    -   -   -          *   (ARG0*      *             *         *   (15
bn/voa/00/voa_0061   0    1       Codover   NNP             *)       -    -   -   -    (PERSON)       *)     *             *         *    15)
bn/voa/00/voa_0061   0    2          says   VBZ          (VP*       say  01   1   -          *      (V*)     *             *         *     -
bn/voa/00/voa_0061   0    3          that    IN        (SBAR*        -    -   -   -          *   (ARG1*      *             *         *     -
bn/voa/00/voa_0061   0    4            in    IN        (S(PP*        -    -   -   -          *        *      *    (ARGM-LOC*         *     -
bn/voa/00/voa_0061   0    5        people   NNS         (NP*))   people   -   1   -          *        *      *             *)        *     -
bn/voa/00/voa_0061   0    6             ,     ,             *        -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0    7            it   PRP          (NP*)       -    -   -   -          *        *      *        (ARG1*)        *    (2)
bn/voa/00/voa_0061   0    8         would    MD          (VP*        -    -   -   -          *        *      *    (ARGM-MOD*)        *     -
bn/voa/00/voa_0061   0    9            be    VB          (VP*        be  03   -   -          *        *    (V*)            *         *     -
bn/voa/00/voa_0061   0   10        tested   VBN          (VP*      test  01   1   -          *        *      *           (V*)        *     -
bn/voa/00/voa_0061   0   11            as    IN          (PP*        -    -   -   -          *        *      *        (ARG2*         *     -
bn/voa/00/voa_0061   0   12    preventive    JJ       (NP(NP*        -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0   13       therapy    NN             *)       -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0   14        rather    RB       (CONJP*        -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0   15          than    IN             *)       -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0   16           one    CD       (NP(NP*)       -    -   -   -          *        *      *             *         *    (9
bn/voa/00/voa_0061   0   17           for    IN          (PP*        -    -   -   -          *        *      *             *         *     -
bn/voa/00/voa_0061   0   18      existing   VBG          (NP*     exist  01   -   -          *        *      *             *       (V*)    -
bn/voa/00/voa_0061   0   19      symptoms   NNS   *)))))))))))       -    -   -   -          *        *)     *             *)   (ARG1*)    9)
bn/voa/00/voa_0061   0   20             .     .            *))       -    -   -   -          *        *      *             *         *     -

bn/voa/00/voa_0061   0    0           Most   JJS  (TOP(S(NP(NP*        -    -   -   -   *             *      *   (ARG1*     -
bn/voa/00/voa_0061   0    1        current    JJ              *        -    -   -   -   *    (ARGM-TMP*)     *        *     -
bn/voa/00/voa_0061   0    2       clinical    JJ              *        -    -   -   -   *    (ARGM-MNR*)     *        *     -
bn/voa/00/voa_0061   0    3         trials   NNS              *)    trial  01   1   -   *           (V*)     *        *     -
bn/voa/00/voa_0061   0    4             in    IN           (PP*        -    -   -   -   *        (ARG1*      *        *     -
bn/voa/00/voa_0061   0    5      Parkinson   NNP        (NP(NP*        -    -   -   -   *             *      *        *   (14
bn/voa/00/voa_0061   0    6             's   POS              *)       -    -   -   -   *             *      *        *     -
bn/voa/00/voa_0061   0    7        Disease   NNP            *)))       -    -   -   -   *             *)     *        *)   14)
bn/voa/00/voa_0061   0    8            are   VBP           (VP*        be  03   -   -   *             *    (V*)       *     -
bn/voa/00/voa_0061   0    9       directed   VBN           (VP*    direct  01   2   -   *             *      *      (V*)    -
bn/voa/00/voa_0061   0   10        towards    IN        (PP(PP*        -    -   -   -   *             *      *   (ARG2*     -
bn/voa/00/voa_0061   0   11    symptomatic    JJ           (NP*        -    -   -   -   *             *      *        *    (9
bn/voa/00/voa_0061   0   12        therapy    NN             *))       -    -   -   -   *             *      *        *     9)
bn/voa/00/voa_0061   0   13             or    CC              *        -    -   -   -   *             *      *        *     -
bn/voa/00/voa_0061   0   14        towards    IN           (PP*        -    -   -   -   *             *      *        *     -
bn/voa/00/voa_0061   0   15           more   RBR      (NP(ADJP*        -    -   -   -   *             *      *        *     -
bn/voa/00/voa_0061   0   16       advanced    JJ              *)       -    -   -   -   *             *      *        *     -
bn/voa/00/voa_0061   0   17       patients   NNS          *)))))       -    -   -   -   *             *      *        *)    -
bn/voa/00/voa_0061   0   18              .     .             *))       -    -   -   -   *             *      *        *     -

bn/voa/00/voa_0061   0    0           This    DT    (TOP(S(NP(NP*          -    -   -   -   *      *       (ARG1*        *        *         *     -
bn/voa/00/voa_0061   0    1           type    NN                *)       type   -   1   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0    2             of    IN             (PP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0    3        therapy    NN           (NP*)))         -    -   -   -   *      *            *)       *        *         *     -
bn/voa/00/voa_0061   0    4             is   VBZ             (VP*          be  03   -   -   *    (V*)           *        *        *         *     -
bn/voa/00/voa_0061   0    5       directed   VBN             (VP*      direct  01   2   -   *      *          (V*)       *        *         *     -
bn/voa/00/voa_0061   0    6        towards    IN             (PP*          -    -   -   -   *      *       (ARG2*        *        *         *     -
bn/voa/00/voa_0061   0    7           more   RBR        (NP(ADJP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0    8          early    JJ                *)         -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0    9       patients   NNS               *))         -    -   -   -   *      *            *)       *        *         *     -
bn/voa/00/voa_0061   0   10           with    IN             (PP*          -    -   -   -   *      *   (ARGM-MNR*        *        *         *     -
bn/voa/00/voa_0061   0   11            the    DT          (NP(NP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   12       emphasis    NN                *)   emphasis   -   1   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   13             on    IN             (PP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   14     preventing   VBG        (S(VP(VP*     prevent  01   1   -   *      *            *      (V*)       *         *     -
bn/voa/00/voa_0061   0   15            the    DT          (NP(NP*          -    -   -   -   *      *            *   (ARG1*        *         *     -
bn/voa/00/voa_0061   0   16    progression    NN                *)         -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   17             of    IN             (PP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   18            the    DT             (NP*          -    -   -   -   *      *            *        *        *         *   (14
bn/voa/00/voa_0061   0   19        disease    NN             *))))         -    -   -   -   *      *            *        *)       *         *    14)
bn/voa/00/voa_0061   0   20         rather    RB          (CONJP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   21           than    IN                *)         -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   22      replacing   VBG         (UCP(VP*     replace  01   1   -   *      *            *        *      (V*)        *     -
bn/voa/00/voa_0061   0   23           lost   VBN             (NP*        lose  02   -   -   *      *            *        *   (ARG1*       (V*)    -
bn/voa/00/voa_0061   0   24        neurons   NNS               *))         -    -   -   -   *      *            *        *        *)   (ARG1*)    -
bn/voa/00/voa_0061   0   25             or    CC                *          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   26           more   RBR     (NP(NP(ADJP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   27    symptomatic    JJ                *)         -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   28          types   NNS                *)       type   -   1   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   29             of    IN             (PP*          -    -   -   -   *      *            *        *        *         *     -
bn/voa/00/voa_0061   0   30       benefits   NNS   (NP*)))))))))))    benefit   -   1   -   *      *            *)       *        *         *     -
bn/voa/00/voa_0061   0   31              .     .               *))         -    -   -   -   *      *            *        *        *         *     -

bn/voa/00/voa_0061   0    0                In    IN     (TOP(S(PP*           -    -   -   -          *   (ARGM-LOC*         *             *             *     -
bn/voa/00/voa_0061   0    1         Stockholm   NNP          (NP*))          -    -   -   -       (GPE)           *)        *             *             *     -
bn/voa/00/voa_0061   0    2                 ,     ,              *           -    -   -   -          *            *         *             *             *     -
bn/voa/00/voa_0061   0    3            Sweden   NNP   (NP(NML(NML*           -    -   -   -       (GPE)      (ARG0*         *             *             *    (0
bn/voa/00/voa_0061   0    4        Carolinska   NNP              *           -    -   -   -      (ORG*            *         *             *             *     -
bn/voa/00/voa_0061   0    5         Institute   NNP              *)          -    -   -   -          *)           *         *             *             *     -
bn/voa/00/voa_0061   0    6    neuroscientist    NN              *)          -    -   -   -          *            *         *             *             *     -
bn/voa/00/voa_0061   0    7              Lars   NNP              *           -    -   -   -   (PERSON*            *         *             *             *     -
bn/voa/00/voa_0061   0    8             Olson   NNP              *)          -    -   -   -          *)           *)        *             *             *     0)
bn/voa/00/voa_0061   0    9              says   VBZ           (VP*          say  01   1   -          *          (V*)        *             *             *     -
bn/voa/00/voa_0061   0   10                if    IN  (SBAR(S(SBAR*           -    -   -   -          *       (ARG1*         *             *    (ARGM-ADV*     -
bn/voa/00/voa_0061   0   11              gene    NN         (S(NP*           -    -   -   -          *            *    (ARG1*)       (ARG0*             *    (5
bn/voa/00/voa_0061   0   12          delivery    NN              *)    delivery  01   1   -          *            *       (V*)            *)            *     5)
bn/voa/00/voa_0061   0   13             works   VBZ           (VP*         work  01   2   -          *            *         *           (V*)            *     -
bn/voa/00/voa_0061   0   14              well    RB         (ADVP*)          -    -   -   -          *            *         *    (ARGM-MNR*)            *     -
bn/voa/00/voa_0061   0   15                in    IN           (PP*           -    -   -   -          *            *         *    (ARGM-LOC*             *     -
bn/voa/00/voa_0061   0   16            people   NNS       (NP*)))))      people   -   1   -          *            *         *             *)            *)    -
bn/voa/00/voa_0061   0   17                 ,     ,              *           -    -   -   -          *            *         *             *             *     -
bn/voa/00/voa_0061   0   18                it   PRP           (NP*)          -    -   -   -          *            *         *             *        (ARG1*)   (5)
bn/voa/00/voa_0061   0   19             would    MD           (VP*           -    -   -   -          *            *         *             *    (ARGM-MOD*)    -
bn/voa/00/voa_0061   0   20                be    VB           (VP*           be  01   1   -          *            *         *             *           (V*)    -
bn/voa/00/voa_0061   0   21               the    DT           (NP*           -    -   -   -          *            *         *             *        (ARG2*     -
bn/voa/00/voa_0061   0   22              best   JJS              *           -    -   -   -          *            *         *             *             *     -
bn/voa/00/voa_0061   0   23         Parkinson   NNP       (NML(NP*           -    -   -   -          *            *         *             *             *   (14
bn/voa/00/voa_0061   0   24                's   POS             *))          -    -   -   -          *            *         *             *             *    14)
bn/voa/00/voa_0061   0   25         treatment    NN              *    treatment   -   1   -          *            *         *             *             *     -
bn/voa/00/voa_0061   0   26               yet    RB   (ADVP*)))))))          -    -   -   -          *            *)        *             *             *)    -
bn/voa/00/voa_0061   0   27                 .     .             *))          -    -   -   -          *            *         *             *             *     -

bn/voa/00/voa_0061   0    0                 It   PRP         (TOP(S(NP*)     -    -    -   -   *        (ARG1*)            *         *             *             *    (5)
bn/voa/00/voa_0061   0    1              would    MD               (VP*      -    -    -   -   *    (ARGM-MOD*)            *         *             *             *     -
bn/voa/00/voa_0061   0    2                 be    VB               (VP*      be  01    1   -   *           (V*)            *         *             *             *     -
bn/voa/00/voa_0061   0    3             better   JJR             (ADJP*)     -    -    -   -   *        (ARG2*)            *         *             *             *     -
bn/voa/00/voa_0061   0    4            because    IN             (SBAR*      -    -    -   -   *    (ARGM-CAU*             *         *             *             *     -
bn/voa/00/voa_0061   0    5                you   PRP           (S(S(NP*)     -    -    -   -   *             *             *    (ARG0*)            *             *     -
bn/voa/00/voa_0061   0    6              would    MD               (VP*      -    -    -   -   *             *    (ARGM-MOD*)        *             *             *     -
bn/voa/00/voa_0061   0    7                n't    RB                  *      -    -    -   -   *             *    (ARGM-NEG*)        *             *             *     -
bn/voa/00/voa_0061   0    8               have    VB               (VP*    have  02   12   -   *             *           (V*)        *             *             *     -
bn/voa/00/voa_0061   0    9                 to    TO             (S(VP*      -    -    -   -   *             *             *         *             *             *     -
bn/voa/00/voa_0061   0   10               take    VB               (VP*    take  01   12   -   *             *             *       (V*)            *             *     -
bn/voa/00/voa_0061   0   11         medication    NN         (NP*)))))))     -    -    -   -   *             *             *    (ARG1*)            *             *     -
bn/voa/00/voa_0061   0   12                and    CC                  *      -    -    -   -   *             *             *         *             *             *     -
bn/voa/00/voa_0061   0   13                you   PRP             (S(NP*)     -    -    -   -   *             *             *         *             *        (ARG0*)    -
bn/voa/00/voa_0061   0   14              would    MD               (VP*      -    -    -   -   *             *             *         *    (ARGM-MOD*)            *     -
bn/voa/00/voa_0061   0   15                n't    RB                  *      -    -    -   -   *             *             *         *    (ARGM-NEG*)            *     -
bn/voa/00/voa_0061   0   16               have    VB               (VP*    have  02   12   -   *             *             *         *           (V*)            *     -
bn/voa/00/voa_0061   0   17                 to    TO             (S(VP*      -    -    -   -   *             *             *         *             *             *     -
bn/voa/00/voa_0061   0   18                 do    VB               (VP*      do  02    1   -   *             *             *         *             *           (V*)    -
bn/voa/00/voa_0061   0   19               cell    NN               (NP*    cell   -    1   -   *             *             *         *             *        (ARG1*     -
bn/voa/00/voa_0061   0   20    transplantation    NN                  *)     -    -    -   -   *             *             *         *             *             *)    -
bn/voa/00/voa_0061   0   21             either    RB   (ADVP*)))))))))))     -    -    -   -   *             *)            *         *             *    (ARGM-ADV*)    -
bn/voa/00/voa_0061   0   22                  .     .                 *))     -    -    -   -   *             *             *         *             *             *     -

bn/voa/00/voa_0061   0    0           It   PRP        (TOP(S(NP*)          -    -    -   -   *        (ARG1*)            *            *    (5)
bn/voa/00/voa_0061   0    1        might    MD              (VP*           -    -    -   -   *    (ARGM-MOD*)            *            *     -
bn/voa/00/voa_0061   0    2           be    VB              (VP*           be  01    1   -   *           (V*)            *            *     -
bn/voa/00/voa_0061   0    3            a    DT           (NP(NP*           -    -    -   -   *        (ARG2*             *            *     -
bn/voa/00/voa_0061   0    4    treatment    NN                 *)   treatment   -    1   -   *             *             *            *     -
bn/voa/00/voa_0061   0    5         that   WDT       (SBAR(WHNP*)          -    -    -   -   *             *             *       (ARG1*)    -
bn/voa/00/voa_0061   0    6          you   PRP            (S(NP*)          -    -    -   -   *             *             *       (ARG0*)    -
bn/voa/00/voa_0061   0    7        would    MD              (VP*           -    -    -   -   *             *    (ARGM-MOD*)           *     -
bn/voa/00/voa_0061   0    8         have    VB              (VP*         have  02   12   -   *             *           (V*)           *     -
bn/voa/00/voa_0061   0    9           to    TO            (S(VP*           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   10           do    VB              (VP*           do  02    1   -   *             *             *          (V*)    -
bn/voa/00/voa_0061   0   11         only    RB    (UCP(UCP(ADVP*           -    -    -   -   *             *             *   (ARGM-TMP*     -
bn/voa/00/voa_0061   0   12         once    RB                 *)          -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   13           or    CC                 *           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   14      perhaps    RB            (ADVP*)          -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   15            a    DT              (NP*           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   16          few    JJ                 *           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   17        times   NNS                *))        time   -    1   -   *             *             *            *     -
bn/voa/00/voa_0061   0   18       during    IN              (PP*           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   19         life    NN           (NP(NP*)        life   -    2   -   *             *             *            *     -
bn/voa/00/voa_0061   0   20         with    IN              (PP*           -    -    -   -   *             *             *            *     -
bn/voa/00/voa_0061   0   21          the    DT              (NP*           -    -    -   -   *             *             *            *   (14
bn/voa/00/voa_0061   0   22      illness    NN   *)))))))))))))))          -    -    -   -   *             *)            *            *)   14)
bn/voa/00/voa_0061   0   23            .     .                *))          -    -    -   -   *             *             *            *     -

bn/voa/00/voa_0061   0    0           Mr.   NNP          (TOP(S(S(NP*            -    -   -   -          *   (ARG0*      *             *            *         *        *            *         *    (0
bn/voa/00/voa_0061   0    1         Olson   NNP                     *)           -    -   -   -    (PERSON)       *)     *             *            *         *        *            *         *     0)
bn/voa/00/voa_0061   0    2          says   VBZ                  (VP*           say  01   1   -          *      (V*)     *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0    3           the    DT           (SBAR(S(NP*            -    -   -   -          *   (ARG1*      *        (ARG1*            *         *        *            *         *    (5
bn/voa/00/voa_0061   0    4     treatment    NN                     *)    treatment   -   1   -          *        *      *             *)           *         *        *            *         *     5)
bn/voa/00/voa_0061   0    5         might    MD                  (VP*            -    -   -   -          *        *      *    (ARGM-MOD*)           *         *        *            *         *     -
bn/voa/00/voa_0061   0    6          also    RB                (ADVP*)           -    -   -   -          *        *      *    (ARGM-DIS*)           *         *        *            *         *     -
bn/voa/00/voa_0061   0    7            be    VB                  (VP*            be  03   -   -          *        *    (V*)            *            *         *        *            *         *     -
bn/voa/00/voa_0061   0    8       applied   VBN                  (VP*         apply  02   1   -          *        *      *           (V*)           *         *        *            *         *     -
bn/voa/00/voa_0061   0    9            to    IN                  (PP*            -    -   -   -          *        *      *        (ARG2*            *         *        *            *         *     -
bn/voa/00/voa_0061   0   10         other    JJ               (NP(NP*            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   11         brain    NN                     *            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   12      diseases   NNS                     *)           -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   13            in    IN           (SBAR(WHPP*            -    -   -   -          *        *      *             *   (ARGM-LOC*         *        *            *         *     -
bn/voa/00/voa_0061   0   14         which   WDT               (WHNP*))           -    -   -   -          *        *      *             *            *)        *        *            *         *     -
bn/voa/00/voa_0061   0   15         nerve    NN                (S(NP*            -    -   -   -          *        *      *             *       (ARG1*         *        *            *         *     -
bn/voa/00/voa_0061   0   16         cells   NNS                     *)         cell   -   1   -          *        *      *             *            *)        *        *            *         *     -
bn/voa/00/voa_0061   0   17    degenerate   VBP       (VP*))))))))))))   degenerate  01   -   -          *        *)     *             *)         (V*)        *        *            *         *     -
bn/voa/00/voa_0061   0   18             ,     ,                     *            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   19           but    CC                     *            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   20            he   PRP                (S(NP*)           -    -   -   -          *        *      *             *            *    (ARG0*)       *            *         *    (0)
bn/voa/00/voa_0061   0   21         warns   VBZ                  (VP*          warn  01   1   -          *        *      *             *            *       (V*)       *            *         *     -
bn/voa/00/voa_0061   0   22            of    IN                  (PP*            -    -   -   -          *        *      *             *            *    (ARG1*        *            *         *     -
bn/voa/00/voa_0061   0   23             a    DT               (NP(NP*            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   24         major    JJ                     *            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   25        hurdle    NN                     *)           -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   26            in    IN                  (PP*            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   27      assuring   VBG                (S(VP*        assure  01   2   -          *        *      *             *            *         *      (V*)           *         *     -
bn/voa/00/voa_0061   0   28      patients   NNS           (SBAR(S(NP*)           -    -   -   -          *        *      *             *            *         *   (ARG2*       (ARG0*)        *     -
bn/voa/00/voa_0061   0   29           get   VBP                  (VP*           get  01   1   -          *        *      *             *            *         *        *          (V*)        *     -
bn/voa/00/voa_0061   0   30           the    DT               (NP(NP*            -    -   -   -          *        *      *             *            *         *        *       (ARG1*         *     -
bn/voa/00/voa_0061   0   31        proper    JJ                     *            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   32          dose    NN                     *)           -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   33            of    IN                  (PP*            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   34          gene    NN                  (NP*            -    -   -   -          *        *      *             *            *         *        *            *         *     -
bn/voa/00/voa_0061   0   35       therapy    NN                   *)))           -    -   -   -          *        *      *             *            *         *        *            *)        *     -
bn/voa/00/voa_0061   0   36       because    IN                (SBAR*            -    -   -   -          *        *      *             *            *         *        *   (ARGM-CAU*         *     -
bn/voa/00/voa_0061   0   37           too    RB           (S(NP(ADJP*            -    -   -   -          *        *      *             *            *         *        *            *    (ARG1*     -
bn/voa/00/voa_0061   0   38          much    JJ                    *))           -    -   -   -          *        *      *             *            *         *        *            *         *)    -
bn/voa/00/voa_0061   0   39            is   VBZ                  (VP*            be  01   1   -          *        *      *             *            *         *        *            *       (V*)    -
bn/voa/00/voa_0061   0   40           bad    JJ   (ADJP*))))))))))))))           -    -   -   -          *        *      *             *            *         *)       *)           *)   (ARG2*)    -
bn/voa/00/voa_0061   0   41             .     .                    *))           -    -   -   -          *        *      *             *            *         *        *            *         *     -

bn/voa/00/voa_0061   0    0               If     IN        (TOP(S(SBAR*          -    -   -   -   *        *    (ARGM-ADV*          *   -
bn/voa/00/voa_0061   0    1              you    PRP              (S(NP*)         -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0    2             over     RB                (VP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0    3               -    HYPH                   *          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0    4        stimulate    VBP                   *          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0    5            other     JJ                (NP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0    6      neighboring    VBG                   *    neighbor  01   1   -   *      (V*)            *          *   -
bn/voa/00/voa_0061   0    7         dopamine     NN                   *          -    -   -   -   *   (ARG1*             *          *   -
bn/voa/00/voa_0061   0    8          neurons    NNS                *))))         -    -   -   -   *        *)            *)         *   -
bn/voa/00/voa_0061   0    9              you    PRP                (NP*)         -    -   -   -   *        *        (ARG0*)         *   -
bn/voa/00/voa_0061   0   10            might     MD                (VP*          -    -   -   -   *        *    (ARGM-MOD*)         *   -
bn/voa/00/voa_0061   0   11              get     VB                (VP*         get  01   1   -   *        *           (V*)         *   -
bn/voa/00/voa_0061   0   12             side     JJ             (NP(NP*          -    -   -   -   *        *        (ARG1*          *   -
bn/voa/00/voa_0061   0   13          effects    NNS                   *)     effect   -   1   -   *        *             *          *   -
bn/voa/00/voa_0061   0   14          similar     JJ              (ADJP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   15               to     IN                (PP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   16             some     DT             (NP(NP*)         -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   17               of     IN                (PP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   18              the     DT             (NP(NP*          -    -   -   -   *        *             *     (ARG1*   -
bn/voa/00/voa_0061   0   19         symptoms    NNS                   *)         -    -   -   -   *        *             *          *)  -
bn/voa/00/voa_0061   0   20             seen    VBN                (VP*         see  01   3   -   *        *             *        (V*)  -
bn/voa/00/voa_0061   0   21               in     IN              (S(PP*          -    -   -   -   *        *             *   (C-ARG1*   -
bn/voa/00/voa_0061   0   22    schizophrenia     NN             (NP(NP*)         -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   23              for     IN                (PP*          -    -   -   -   *        *             *          *   -
bn/voa/00/voa_0061   0   24         instance     NN   (NP*))))))))))))))         -    -   -   -   *        *             *)         *)  -
bn/voa/00/voa_0061   0   25                .      .                  *))         -    -   -   -   *        *             *          *   -

bn/voa/00/voa_0061   0    0           For    IN       (TOP(S(PP*          -    -   -   -   *        *    (ARGM-ADV*         *         *      *             *   -
bn/voa/00/voa_0061   0    1           use    NN          (NP(NP*)        use  01   1   -   *      (V*)            *         *         *      *             *   -
bn/voa/00/voa_0061   0    2            in    IN             (PP*          -    -   -   -   *   (ARG2*             *         *         *      *             *   -
bn/voa/00/voa_0061   0    3      patients   NNS          (NP*))))         -    -   -   -   *        *)            *)        *         *      *             *   -
bn/voa/00/voa_0061   0    4           one   PRP             (NP*)         -    -   -   -   *        *        (ARG0*)   (ARG0*)        *      *             *   -
bn/voa/00/voa_0061   0    5         would    MD             (VP*          -    -   -   -   *        *    (ARGM-MOD*)        *         *      *             *   -
bn/voa/00/voa_0061   0    6          like    VB             (VP*        like  02   1   -   *        *           (V*)        *         *      *             *   -
bn/voa/00/voa_0061   0    7            to    TO           (S(VP*          -    -   -   -   *        *        (ARG1*         *         *      *             *   -
bn/voa/00/voa_0061   0    8          have    VB             (VP*        have  03   2   -   *        *             *       (V*)        *      *             *   -
bn/voa/00/voa_0061   0    9             a    DT          (NP(NP*          -    -   -   -   *        *             *    (ARG1*         *      *        (ARG0*   -
bn/voa/00/voa_0061   0   10        system    NN                *)         -    -   -   -   *        *             *         *         *      *             *)  -
bn/voa/00/voa_0061   0   11         where   WRB    (SBAR(WHADVP*)         -    -   -   -   *        *             *         *         *      *      (R-ARG0*)  -
bn/voa/00/voa_0061   0   12           the    DT        (S(NP(NP*          -    -   -   -   *        *             *         *         *      *        (ARG1*   -
bn/voa/00/voa_0061   0   13      activity    NN                *)   activity   -   2   -   *        *             *         *         *      *             *   -
bn/voa/00/voa_0061   0   14            of    IN             (PP*          -    -   -   -   *        *             *         *         *      *             *   -
bn/voa/00/voa_0061   0   15           the    DT             (NP*          -    -   -   -   *        *             *         *         *      *             *   -
bn/voa/00/voa_0061   0   16     delivered   VBN                *     deliver  01   -   -   *        *             *         *       (V*)     *             *   -
bn/voa/00/voa_0061   0   17          gene    NN              *)))         -    -   -   -   *        *             *         *    (ARG1*)     *             *)  -
bn/voa/00/voa_0061   0   18         could    MD             (VP*          -    -   -   -   *        *             *         *         *      *    (ARGM-MOD*)  -
bn/voa/00/voa_0061   0   19            be    VB             (VP*          be  03   -   -   *        *             *         *         *    (V*)            *   -
bn/voa/00/voa_0061   0   20    controlled   VBN   (VP*)))))))))))    control  01   1   -   *        *             *)        *)        *      *           (V*)  -
bn/voa/00/voa_0061   0   21             .     .               *))         -    -   -   -   *        *             *         *         *      *             *   -

bn/voa/00/voa_0061   0    0       Jeffery   NNP        (TOP(S(NP*          -    -   -   -   (PERSON*   (ARG0*      *             *        *            *    (15
bn/voa/00/voa_0061   0    1       Cooover   NNP                 *)         -    -   -   -          *)       *)     *             *        *            *     15)
bn/voa/00/voa_0061   0    2          says   VBZ              (VP*         say  01   1   -          *      (V*)     *             *        *            *      -
bn/voa/00/voa_0061   0    3            he   PRP       (SBAR(S(NP*)         -    -   -   -          *   (ARG1*      *        (ARG0*)       *            *    (15)
bn/voa/00/voa_0061   0    4            is   VBZ              (VP*          be  03   -   -          *        *    (V*)            *        *            *      -
bn/voa/00/voa_0061   0    5           now    RB            (ADVP*)         -    -   -   -          *        *      *    (ARGM-TMP*)       *            *      -
bn/voa/00/voa_0061   0    6       testing   VBG              (VP*        test  01   1   -          *        *      *           (V*)       *            *      -
bn/voa/00/voa_0061   0    7          ways   NNS           (NP(NP*)        way   -   2   -          *        *      *        (ARG1*        *            *      -
bn/voa/00/voa_0061   0    8            of    IN              (PP*          -    -   -   -          *        *      *             *        *            *      -
bn/voa/00/voa_0061   0    9    regulating   VBG            (S(VP*    regulate  01   1   -          *        *      *             *      (V*)           *      -
bn/voa/00/voa_0061   0   10          gene    NN           (NP(NP*          -    -   -   -          *        *      *             *   (ARG1*       (ARG1*)     -
bn/voa/00/voa_0061   0   11      delivery    NN                 *)   delivery  01   1   -          *        *      *             *        *          (V*)     -
bn/voa/00/voa_0061   0   12            in    IN              (PP*          -    -   -   -          *        *      *             *        *   (ARGM-LOC*      -
bn/voa/00/voa_0061   0   13       monkeys   NNS   (NP*))))))))))))         -    -   -   -          *        *)     *             *)       *)           *)     -
bn/voa/00/voa_0061   0   14             .     .                *))         -    -   -   -          *        *      *             *        *            *      -

bn/voa/00/voa_0061   0    0            He   PRP   (TOP(S(NP*)           -    -   -   -        *    (ARG0*)      (ARG0*)     *        *        *    (15)
bn/voa/00/voa_0061   0    1         hopes   VBZ         (VP*          hope  01   1   -        *       (V*)           *      *        *        *      -
bn/voa/00/voa_0061   0    2            to    TO       (S(VP*            -    -   -   -        *    (ARG1*            *      *        *        *      -
bn/voa/00/voa_0061   0    3           try    VB         (VP*           try  01   2   -        *         *          (V*)     *        *        *      -
bn/voa/00/voa_0061   0    4           the    DT         (NP*            -    -   -   -        *         *       (ARG1*      *        *        *     (2
bn/voa/00/voa_0061   0    5     procedure    NN            *)    procedure  01   1   -        *         *            *)   (V*)       *        *      2)
bn/voa/00/voa_0061   0    6            in    IN         (PP*            -    -   -   -        *         *   (ARGM-LOC*      *        *        *      -
bn/voa/00/voa_0061   0    7        people   NNS        (NP*))       people   -   1   -        *         *            *)     *        *        *      -
bn/voa/00/voa_0061   0    8        within    IN         (PP*            -    -   -   -        *         *   (ARGM-TMP*      *        *        *      -
bn/voa/00/voa_0061   0    9          five    CD         (NP*            -    -   -   -   (DATE*         *            *      *        *        *      -
bn/voa/00/voa_0061   0   10         years   NNS           *))           -    -   -   -        *)        *            *)     *        *        *      -
bn/voa/00/voa_0061   0   11     following   VBG         (PP*        follow  01   2   -        *         *   (ARGM-TMP*      *      (V*)       *      -
bn/voa/00/voa_0061   0   12            US   NNP     (NP(NML*            -    -   -   -     (GPE)        *            *      *   (ARG2*   (ARG0*      -
bn/voa/00/voa_0061   0   13    government    NN            *)   government   -   1   -        *         *            *      *        *        *)     -
bn/voa/00/voa_0061   0   14        review    NN       *))))))       review  01   1   -        *         *)           *)     *        *)     (V*)     -
bn/voa/00/voa_0061   0   15             .     .           *))           -    -   -   -        *         *            *      *        *        *      -

bn/voa/00/voa_0061   0   0         David   NNP  (TOP(FRAG(NP*   -   -   -   -   (PERSON*   (21
bn/voa/00/voa_0061   0   1       McAlary   NNP              *)  -   -   -   -          *)   21)
bn/voa/00/voa_0061   0   2             ,     ,              *   -   -   -   -          *     -
bn/voa/00/voa_0061   0   3           VOA   NNP           (NP*   -   -   -   -      (ORG*   (16
bn/voa/00/voa_0061   0   4          News   NNP              *)  -   -   -   -          *)   16)
bn/voa/00/voa_0061   0   5             ,     ,              *   -   -   -   -          *     -
bn/voa/00/voa_0061   0   6    Washington   NNP           (NP*)  -   -   -   -       (GPE)    -
bn/voa/00/voa_0061   0   7             .     .             *))  -   -   -   -          *     -

#end document
